Literature DB >> 19303903

Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling.

Yingkui Yang1, Minying Cai, Min Chen, Hongchang Qu, David McPherson, Victor Hruby, Carroll M Harmon.   

Abstract

Melanocortin 4 receptor (MC4R) plays an important role in the regulation of food intake and glucose homeostasis. Synthetic nonpeptide compound N- (3R)-1 4-tetrahydroisoquinolinium-3-ylcarbonyl-(1R)-1-(4-chlorobenzyl)-2-4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl-2-oxoethylamine (THIQ) is a potent agonist at MC4R but not at hMC2R. In this study, we utilized two approaches (chimeric receptor and site-directed mutagenesis) to narrow down the key amino acid residues of MC4R responsible for THIQ binding and signaling. Cassette substitutions of the second, third, fourth, fifth, and sixth transmembrane regions (TMs) of the human MC4R (hMC4R) with the homologous regions of hMC2R were constructed. Our results indicate that the cassette substitutions of these TMs of the hMC4R with homologous regions of the hMC2R did not significantly alter THIQ binding affinity and potency except the substitution of the hMC4R TM3, suggesting that the conserved amino acid residues in these TMs of the hMC4R are main potential candidates for THIQ binding and signaling while non conserved residues in TM3 of MC4R may also be involved. Nineteen MC4R mutants were then created, including 13 conserved amino acid residues and 6 non-conserved amino acid residues. Our results indicate that seven conserved residue [E100 (TM2), D122 (TM3), D126 (TM3), F254 (TM6), W258 (TM6), F261 (TM6), H264 (TM6)] are important for THIQ binding and three non-conserved residues [N123 (TM3), I129 (TM3) and S131 (TM3)] are involved in THIQ selectivity. In conclusion, our results suggest that THIQ utilize both conserved and non-conserved amino acid residues for binding and signaling at hMC4R and non conserved residues may be responsible for MC4R selectivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303903      PMCID: PMC3216638          DOI: 10.1016/j.regpep.2009.03.006

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  62 in total

1.  Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

Authors:  Iyassu K Sebhat; William J Martin; Zhixiong Ye; Khaled Barakat; Ralph T Mosley; David B R Johnston; Raman Bakshi; Brenda Palucki; David H Weinberg; Tanya MacNeil; Rubana N Kalyani; Rui Tang; Ralph A Stearns; Randy R Miller; Constantin Tamvakopoulos; Alison M Strack; Erin McGowan; Doreen E Cashen; Jennifer E Drisko; Gary J Hom; Andrew D Howard; D Euan MacIntyre; Lex H T van der Ploeg; Arthur A Patchett; Ravi P Nargund
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

Review 2.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.

Authors:  Kurt Kristiansen
Journal:  Pharmacol Ther       Date:  2004-07       Impact factor: 12.310

3.  Drug treatment of obesity: don't throw the baby out with the bath water.

Authors:  G Bray
Journal:  Am J Clin Nutr       Date:  1998-01       Impact factor: 7.045

4.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

5.  Calculating receptor number from binding experiments using same compound as radioligand and competitor.

Authors:  A DeBlasi; K O'Reilly; H J Motulsky
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

6.  Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling.

Authors:  Min Chen; Charles J Aprahamian; Robert A Kesterson; Carroll M Harmon; Yingkui Yang
Journal:  Biochemistry       Date:  2007-09-18       Impact factor: 3.162

7.  Contribution of melanocortin receptor exoloops to Agouti-related protein binding.

Authors:  Y K Yang; C J Dickinson; Q Zeng; J Y Li; D A Thompson; I Gantz
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

8.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

9.  Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model.

Authors:  Tricia J Vos; Andrei Caracoti; Jennifer L Che; Mingshi Dai; Cheryl A Farrer; Nancy E Forsyth; Stacey V Drabic; Robert A Horlick; Diana Lamppu; David L Yowe; Suresh Balani; Ping Li; Hang Zeng; Ingrid B J K Joseph; Luis E Rodriguez; Martin P Maguire; Michael A Patane; Christopher F Claiborne
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

10.  The probable arrangement of the helices in G protein-coupled receptors.

Authors:  J M Baldwin
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  7 in total

1.  Approaches to the rational design of selective melanocortin receptor antagonists.

Authors:  Victor J Hruby; Minying Cai; Joel Nyberg; Dhanasekaran Muthu
Journal:  Expert Opin Drug Discov       Date:  2011-03-24       Impact factor: 6.098

2.  Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists.

Authors:  Minying Cai; Udaya Kiran Marelli; Blake Mertz; Johannes G Beck; Florian Opperer; Florian Rechenmacher; Horst Kessler; Victor J Hruby
Journal:  Biochemistry       Date:  2017-08-01       Impact factor: 3.162

Review 3.  Structure, function and regulation of the melanocortin receptors.

Authors:  Yingkui Yang
Journal:  Eur J Pharmacol       Date:  2011-01-03       Impact factor: 4.432

4.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

5.  Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.

Authors:  Bethany A Falls; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-08-13       Impact factor: 4.418

6.  Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.

Authors:  Kathryn L Chapman; Gemma K Kinsella; Alan Cox; Dan Donnelly; John B C Findlay
Journal:  J Mol Biol       Date:  2010-06-19       Impact factor: 5.469

Review 7.  MC4R biased signalling and the conformational basis of biological function selections.

Authors:  Zekun Liu; Victor J Hruby
Journal:  J Cell Mol Med       Date:  2022-07-11       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.